Navidea biopharmaceuticals announces the extension of plan designed to protect nols and other tax assets

Columbus, ohio--(business wire)--navidea biopharmaceuticals, inc. (“navidea” or the “company”) today announced that its board of directors has elected to extend the company's section 382 rights agreement (the “section 382 rights plan”). originally adopted on april 7, 2022, and set to expire on april 6, 2025, the plan has now been extended to april 7, 2027. the section 382 rights plan is designed to safeguard navidea's ability to utilize its net operating loss carryforwards (“nols”) and other ta.
NAVB Ratings Summary
NAVB Quant Ranking